Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia
Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia
复制标题
DOI：
10.1016/j.jpsychires.2019.03.019
复制
发表时间：
2019-06-01
影响因子：
4.8
通讯作者：
Otto, Markus
中科院分区：
文献类型：
--
作者：
Al Shweiki, M. H. D. Rami;Steinacker, Petra;Otto, Markus
行为变异性额颞叶痴呆（bvFTD）与原发性精神障碍（如抑郁症、精神分裂症谱系和双相情感障碍）的重叠症状对中老年人群的bvFTD鉴别诊断提出了挑战。神经丝是神经元中的细胞骨架蛋白，一些研究报道神经退行性疾病和精神疾病的脑脊液中神经丝轻链（NfL）水平升高。该研究旨在确定血清NfL水平作为区分bvFTD和精神障碍的生物标志物的效用。本研究采用单分子阵列（Simoa）技术检测了精神分裂症（n = 11）、抑郁症（n = 28）、双相情感障碍（n = 11）、bvFTD （n = 20）和对照组（n = 27）患者血清中NfL的水平。与对照组相比，精神分裂症、抑郁症和躁郁症患者血清NfL水平无显著变化（p < 0.99）。与对照组（p < 0.0001）、抑郁症（p < 0.0001）、精神分裂症（p < 0.0002）和双相情感障碍患者（p < 0.0083）相比，bvFTD患者血清NfL水平显著升高。我们建议血清NfL作为区分bvFTD与精神疾病的生物标志物，并排除精神疾病过程中的神经退行性变。
The overlapping symptoms of behavioural variant frontotemporal dementia (bvFTD) and primary psychiatric disorders (such as depressive disorder, schizophrenia spectrum, and bipolar disorder) present a challenge for the differential diagnosis of bvFTD in middle and older-aged people. Neurofilaments are cytoskeletal proteins in the neurons, and several studies have reported elevated levels of neurofilament light chain (NfL) in cerebrospinal fluid of neurodegenerative as well as psychiatric disorders. The study aims to determine the utility of serum NfL levels as a biomarker to differentiate between bvFTD and psychiatric disorder. In our study, we investigated the levels of NfL in the serum of schizophrenia (n = 11), depression (n = 28), bipolar (n = 11), bvFTD (n = 20) patients and controls (n = 27) by single molecule array (Simoa) technology. The schizophrenia, depression and bipolar patients did not show significant changes in serum NfL levels in comparison to the control group (p > 0.99). The serum NfL levels were significantly elevated in bvFTD patients in comparison to the control cohort (p < 0.0001), depression (p < 0.0001), schizophrenia (p < 0.0002) and bipolar patients (p < 0.0083). We propose serum NfL as a biomarker to differentiate bvFTD from psychiatric disorders and to rule out neurodegeneration in the course of psychiatric disorders.